When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

U.S. stocks ended the week mostly higher, with the S&P 500 (+0.6%) and Nasdaq (+1.5%) setting new record highs, lifted by strong Q2 earnings and softer-than-expected inflation data. June retail sales ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

Second-quarter profit jumps 46% at Netflix, while a report says Union Pacific is in early-stage talks to buy smaller railroad ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...